Who are batch 1 of Ad5-nCoV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Influenza, Moderna mRNA-1273 COVID-19 vaccine, Inactivated SARS-CoV-2 Vaccine (Vero cell）, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, TT, BNT162b2 (2025/2026 formulation).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/batch-1-of-ad5-ncov.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

batch 1 of Ad5-nCoV — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

batch 1 of Ad5-nCoV (batch 1 of Ad5-nCoV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: viral vector vaccine. Area: Immunology / Infectious Disease.

marketed viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

batch 1 of Ad5-nCoV (batch 1 of Ad5-nCoV) — Jiangsu Province Centers for Disease Control and Prevention. Ad5-nCoV is a recombinant adenovirus type 5 vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
batch 1 of Ad5-nCoV TARGET	batch 1 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Influenza	Influenza and COVID-19 Combination A	BioNTech	marketed	Non-Standardized Plant Allergenic Extract [EPC]	SARS-CoV-2 spike protein and influenza hemagglutinin protein
Moderna mRNA-1273 COVID-19 vaccine	Moderna mRNA-1273 COVID-19 vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Inactivated SARS-CoV-2 Vaccine (Vero cell）	Inactivated SARS-CoV-2 Vaccine (Vero cell）	Sinovac Research and Development Co., Ltd.	marketed	inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose	variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
TT	TT	CanSino Biologics Inc.	marketed	Viral vector vaccine	SARS-CoV-2 spike protein
BNT162b2 (2025/2026 formulation)	bnt162b2-2025-2026-formulation	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (viral vector vaccine class)

Jiangsu Province Centers for Disease Control and Prevention · 3 drugs in this class
University Medical Center Groningen · 1 drug in this class
Vinbiocare Biotechnology Joint Stock Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). batch 1 of Ad5-nCoV — Competitive Intelligence Brief. https://druglandscape.com/ci/batch-1-of-ad5-ncov. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab